Clarivate PLC (NYSE:CLVT) Receives $3.22 Consensus PT from Analysts

Clarivate PLC (NYSE:CLVT) has been given a consensus rating of “Reduce” by the eight analysts that are covering the firm, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $3.2167.

CLVT has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Clarivate in a research report on Friday, March 27th. Royal Bank Of Canada reduced their price objective on Clarivate from $5.00 to $3.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 25th. Barclays reduced their price objective on Clarivate from $4.00 to $2.40 and set an “underweight” rating on the stock in a research report on Wednesday, February 25th. Citigroup reduced their price objective on Clarivate from $4.25 to $2.80 and set a “neutral” rating on the stock in a research report on Wednesday, March 4th. Finally, Wall Street Zen upgraded Clarivate from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd.

Clarivate Stock Performance

Shares of CLVT stock opened at $2.21 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 0.89. The business’s 50 day moving average is $2.52 and its two-hundred day moving average is $2.74. The company has a market capitalization of $1.41 billion, a P/E ratio of -10.50 and a beta of 1.36. Clarivate has a 12-month low of $1.66 and a 12-month high of $4.77.

Clarivate (NYSE:CLVT) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. The firm had revenue of $585.50 million for the quarter, compared to analyst estimates of $569.50 million. Clarivate had a positive return on equity of 8.82% and a negative net margin of 5.61%.The business’s revenue was down 1.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.14 earnings per share. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. Analysts expect that Clarivate will post 0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Clarivate

A number of institutional investors have recently added to or reduced their stakes in CLVT. Cetera Investment Advisers increased its holdings in shares of Clarivate by 11.2% during the 2nd quarter. Cetera Investment Advisers now owns 26,034 shares of the company’s stock worth $112,000 after purchasing an additional 2,617 shares during the period. California State Teachers Retirement System increased its holdings in shares of Clarivate by 0.9% during the 2nd quarter. California State Teachers Retirement System now owns 303,147 shares of the company’s stock worth $1,304,000 after purchasing an additional 2,788 shares during the period. Envestnet Asset Management Inc. increased its holdings in shares of Clarivate by 3.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 77,275 shares of the company’s stock worth $296,000 after purchasing an additional 2,884 shares during the period. IFP Advisors Inc increased its stake in Clarivate by 8.1% in the third quarter. IFP Advisors Inc now owns 41,426 shares of the company’s stock valued at $170,000 after acquiring an additional 3,117 shares during the period. Finally, Hsbc Holdings PLC increased its stake in Clarivate by 4.3% in the second quarter. Hsbc Holdings PLC now owns 116,648 shares of the company’s stock valued at $500,000 after acquiring an additional 4,792 shares during the period. Hedge funds and other institutional investors own 85.72% of the company’s stock.

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.